JP2012528597A5 - - Google Patents

Download PDF

Info

Publication number
JP2012528597A5
JP2012528597A5 JP2012514147A JP2012514147A JP2012528597A5 JP 2012528597 A5 JP2012528597 A5 JP 2012528597A5 JP 2012514147 A JP2012514147 A JP 2012514147A JP 2012514147 A JP2012514147 A JP 2012514147A JP 2012528597 A5 JP2012528597 A5 JP 2012528597A5
Authority
JP
Japan
Prior art keywords
gpvi ligand
gpvi
ring
ligand
shaft portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012514147A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012528597A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/037319 external-priority patent/WO2010141771A1/en
Publication of JP2012528597A publication Critical patent/JP2012528597A/ja
Publication of JP2012528597A5 publication Critical patent/JP2012528597A5/ja
Pending legal-status Critical Current

Links

JP2012514147A 2009-06-03 2010-06-03 血小板グリコプロテインｖｉの核酸調節因子 Pending JP2012528597A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18384709P 2009-06-03 2009-06-03
US61/183,847 2009-06-03
US30095110P 2010-02-03 2010-02-03
US61/300,951 2010-02-03
PCT/US2010/037319 WO2010141771A1 (en) 2009-06-03 2010-06-03 Nucleic acid modulators of glycoprotein vi

Publications (2)

Publication Number Publication Date
JP2012528597A JP2012528597A (ja) 2012-11-15
JP2012528597A5 true JP2012528597A5 (https=) 2013-07-18

Family

ID=42697339

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012514147A Pending JP2012528597A (ja) 2009-06-03 2010-06-03 血小板グリコプロテインｖｉの核酸調節因子

Country Status (11)

Country Link
US (1) US8318923B2 (https=)
EP (1) EP2438169B1 (https=)
JP (1) JP2012528597A (https=)
KR (1) KR20120055529A (https=)
CN (1) CN102459599A (https=)
AU (1) AU2010256511B2 (https=)
CA (1) CA2764449A1 (https=)
IL (1) IL216725A0 (https=)
RU (1) RU2571660C2 (https=)
SG (1) SG176644A1 (https=)
WO (1) WO2010141771A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8790924B2 (en) 2006-10-19 2014-07-29 Duke University Reversible platelet inhibition
WO2012050611A2 (en) * 2010-10-13 2012-04-19 Duke University Aptamers to glycoprotein vi
US9687529B2 (en) 2011-05-05 2017-06-27 Duke University Method of controlling coagulation
US8735367B2 (en) * 2011-06-27 2014-05-27 University Of Utah Research Foundation Small molecule-dependent split aptamer ligation
CA2894174A1 (en) * 2012-12-06 2014-06-12 Regado Biosciences Inc. Oligonucleotide formulation
WO2014193800A2 (en) 2013-05-28 2014-12-04 The Johns Hopkins University Aptamers for the treatment of sickle cell disease
TWI849231B (zh) * 2015-03-03 2024-07-21 香港商南沙生物科技（香港）有限公司 聚乙二醇化介白素-11之組合物及方法
WO2016176426A1 (en) 2015-04-28 2016-11-03 Duke University Thrombus imaging aptamers and methods of using same
EP3512526A4 (en) 2016-09-16 2020-05-27 Duke University VON WILLEBRAND FACTOR (VWF) TARGETING AGENTS AND METHODS OF USE
CN108823247A (zh) * 2018-06-05 2018-11-16 山东省医学科学院附属医院 一种人源化cd-19嵌合抗原受体t淋巴细胞载体及其应用
CN110951866A (zh) * 2019-12-27 2020-04-03 河南中医药大学 一种检测gpvi基因启动子区甲基化水平的引物及其检测方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ237244A (en) * 1990-03-02 1992-10-28 Bio Technology General Corp Cloning and production of human von willebrand factor analogues and compositions thereof
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5780228A (en) 1990-06-11 1998-07-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5789163A (en) 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Enzyme linked oligonucleotide assays (ELONAS)
US5648214A (en) 1990-06-11 1997-07-15 University Research Corporation High-affinity oligonucleotide ligands to the tachykinin substance P
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US6127119A (en) 1990-06-11 2000-10-03 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US6716580B2 (en) 1990-06-11 2004-04-06 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6147204A (en) 1990-06-11 2000-11-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5919761A (en) 1992-08-14 1999-07-06 The Board Of Regents Of The University Of Michigan Peptides for heparin and low molecular weight heparin anticoagulation reversal
US6306598B1 (en) 1992-11-13 2001-10-23 Regents Of The University Of California Nucleic acid-coupled colorimetric analyte detectors
US6682886B1 (en) 1994-04-28 2004-01-27 Gilead Sciences, Inc. Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
US6229002B1 (en) * 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
DE69921773D1 (de) 1998-01-16 2004-12-16 Univ Johns Hopkins Orale verabreichung von nukleinsäure-impstoffen durch partikelkomplexe
US6428956B1 (en) 1998-03-02 2002-08-06 Isis Pharmaceuticals, Inc. Mass spectrometric methods for biomolecular screening
US6548302B1 (en) 1998-06-18 2003-04-15 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US6383752B1 (en) 1999-03-31 2002-05-07 Hybridon, Inc. Pseudo-cyclic oligonucleobases
US6280943B1 (en) 1999-06-17 2001-08-28 Gilead Sciences, Inc. 2′-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands
US6245527B1 (en) 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7655787B2 (en) * 2000-08-23 2010-02-02 Purdue Research Foundation pRNA chimera
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
US7312325B2 (en) 2000-09-26 2007-12-25 Duke University RNA aptamers and methods for identifying the same
EP1411969A1 (en) 2001-03-08 2004-04-28 MERCK PATENT GmbH Modified protamine with reduced immunogenicity
DK2070939T3 (da) * 2001-05-25 2014-06-23 Univ Duke Modulatorer af farmakologiske midler
WO2006061650A2 (en) * 2004-12-10 2006-06-15 Trigen Gmbh Methods, products and uses involving platelets and/or the vasculature
EP1538165A1 (en) * 2003-12-03 2005-06-08 Procorde GmbH Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4
EP2460811A1 (en) * 2004-04-22 2012-06-06 Regado Biosciences, Inc. Improved modulators of coagulation factors
US7645592B2 (en) 2004-04-29 2010-01-12 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods of use thereof
KR100578382B1 (ko) 2004-07-16 2006-05-11 나재운 항암제의 전달체용 수용성 키토산 나노입자 및 그 제조방법
EP1789096A4 (en) * 2004-09-07 2009-07-08 Archemix Corp APTAMERS FOR THE VON WILLEBRAND FACTOR AND ITS USE AS THERAPEUTICS FOR THROMBOTIC DISEASES
RU2410431C2 (ru) * 2005-11-25 2011-01-27 Мологен Аг Днк-конструкции для специфического ингибирования экспрессии генов посредством рнк-интерференции
RU2568579C2 (ru) 2006-05-26 2015-11-20 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Введение противосвертывающей системы reg1
US8158595B2 (en) * 2006-11-09 2012-04-17 California Institute Of Technology Modular aptamer-regulated ribozymes

Similar Documents

Publication Publication Date Title
JP2012528597A5 (https=)
Caffery et al. Vectors for glioblastoma gene therapy: viral & non-viral delivery strategies
Lundstrom Viral vectors for COVID-19 vaccine development
Cheng et al. CRISPR/Cas9 delivery system engineering for genome editing in therapeutic applications
Riccardi et al. Dimeric and multimeric DNA aptamers for highly effective protein recognition
JP2012505657A5 (https=)
JP2020022459A5 (https=)
JP2014509685A5 (https=)
JP2013510561A5 (https=)
Borgoyakova et al. Self-assembled particles combining SARS-CoV-2 RBD protein and RBD DNA vaccine induce synergistic enhancement of the humoral response in mice
JP2015096070A5 (https=)
JP2018522566A5 (https=)
JP2017523781A5 (https=)
JP2014054250A5 (https=)
RU2016122168A (ru) Антисмысловые конъюгаты, направленные на аполипопротеин b
JP2013510584A5 (https=)
JP2008525033A5 (https=)
Prangishvili et al. Genomics and biology of Rudiviruses, a model for the study of virus–host interactions in Archaea
Smith et al. Clinical development of a cytomegalovirus DNA vaccine: from product concept to pivotal phase 3 trial
RU2011154087A (ru) Модуляторы гликопротеина vi, представляющие собой нуклеиновую кислоту
Kairuz et al. Advancing mRNA technologies for therapies and vaccines: An African context
Shen et al. Single-stranded circular DNA theranostics
JP2011524745A5 (https=)
Gamper et al. Functionalized tobacco mosaic virus coat protein monomers and oligomers as nanocarriers for anti-cancer peptides
JP2020514299A5 (https=)